share_log

Strong Week for Jiangsu SOPO Chemical (SHSE:600746) Shareholders Doesn't Alleviate Pain of Three-year Loss

Strong Week for Jiangsu SOPO Chemical (SHSE:600746) Shareholders Doesn't Alleviate Pain of Three-year Loss

江蘇索普化學(上海證券交易所代碼:600746)股東表現強勁的一週並未緩解三年虧損的痛苦
Simply Wall St ·  03/22 08:20

Many investors define successful investing as beating the market average over the long term. But in any portfolio, there are likely to be some stocks that fall short of that benchmark. We regret to report that long term Jiangsu SOPO Chemical Co. Ltd. (SHSE:600746) shareholders have had that experience, with the share price dropping 42% in three years, versus a market decline of about 11%. And more recent buyers are having a tough time too, with a drop of 24% in the last year. Furthermore, it's down 10% in about a quarter. That's not much fun for holders.

許多投資者將成功的投資定義爲長期超過市場平均水平。但是在任何投資組合中,都可能有一些股票未達到該基準。我們很遺憾地報告,從長遠來看,江蘇索波化工有限公司有限公司(上海證券交易所代碼:600746)的股東也有過這樣的經歷,股價在三年內下跌了42%,而市場下跌了約11%。最近的買家也處境艱難,去年下降了24%。此外,它在大約一個季度內下降了10%。對於持有者來說,這並不好玩。

Although the past week has been more reassuring for shareholders, they're still in the red over the last three years, so let's see if the underlying business has been responsible for the decline.

儘管過去一週令股東更加放心,但在過去三年中,他們仍處於虧損狀態,所以讓我們看看基礎業務是否是造成下降的原因。

While the efficient markets hypothesis continues to be taught by some, it has been proven that markets are over-reactive dynamic systems, and investors are not always rational. One imperfect but simple way to consider how the market perception of a company has shifted is to compare the change in the earnings per share (EPS) with the share price movement.

儘管一些人繼續教導高效市場假說,但事實證明,市場是反應過度的動態系統,投資者並不總是理性的。考慮市場對公司的看法發生了怎樣的變化的一種不完美但簡單的方法是將每股收益(EPS)的變化與股價走勢進行比較。

Jiangsu SOPO Chemical saw its share price decline over the three years in which its EPS also dropped, falling to a loss. Since the company has fallen to a loss making position, it's hard to compare the change in EPS with the share price change. But it's safe to say we'd generally expect the share price to be lower as a result!

江蘇索波化工的股價在三年中下跌,其每股收益也下降至虧損。由於該公司已跌至虧損狀態,因此很難將每股收益的變化與股價的變化進行比較。但可以肯定地說,我們通常預計股價會因此而降低!

The image below shows how EPS has tracked over time (if you click on the image you can see greater detail).

下圖顯示了 EPS 在一段時間內的跟蹤情況(如果你點擊圖片,你可以看到更多細節)。

earnings-per-share-growth
SHSE:600746 Earnings Per Share Growth March 22nd 2024
上海證券交易所:600746 每股收益增長 2024 年 3 月 22 日

Before buying or selling a stock, we always recommend a close examination of historic growth trends, available here.

在買入或賣出股票之前,我們始終建議仔細研究歷史增長趨勢,可在此處查閱。

What About Dividends?

分紅呢?

When looking at investment returns, it is important to consider the difference between total shareholder return (TSR) and share price return. Whereas the share price return only reflects the change in the share price, the TSR includes the value of dividends (assuming they were reinvested) and the benefit of any discounted capital raising or spin-off. It's fair to say that the TSR gives a more complete picture for stocks that pay a dividend. In the case of Jiangsu SOPO Chemical, it has a TSR of -35% for the last 3 years. That exceeds its share price return that we previously mentioned. The dividends paid by the company have thusly boosted the total shareholder return.

在考慮投資回報時,重要的是要考慮兩者之間的區別 股東總回報 (TSR) 和 股價回報。儘管股價回報率僅反映股價的變化,但股東總回報率包括股息的價值(假設已進行再投資)以及任何折扣融資或分拆的收益。可以公平地說,股東總回報率爲支付股息的股票提供了更完整的畫面。就江蘇索普化工而言,其在過去三年的股東回報率爲-35%。這超過了我們之前提到的其股價回報率。因此,該公司支付的股息提高了 股東回報。

A Different Perspective

不同的視角

We regret to report that Jiangsu SOPO Chemical shareholders are down 22% for the year (even including dividends). Unfortunately, that's worse than the broader market decline of 11%. However, it could simply be that the share price has been impacted by broader market jitters. It might be worth keeping an eye on the fundamentals, in case there's a good opportunity. Unfortunately, last year's performance may indicate unresolved challenges, given that it was worse than the annualised loss of 0.8% over the last half decade. Generally speaking long term share price weakness can be a bad sign, though contrarian investors might want to research the stock in hope of a turnaround. It's always interesting to track share price performance over the longer term. But to understand Jiangsu SOPO Chemical better, we need to consider many other factors. Case in point: We've spotted 1 warning sign for Jiangsu SOPO Chemical you should be aware of.

我們遺憾地報告,江蘇索普化工的股東今年下跌了22%(甚至包括股息)。不幸的是,這比整個市場11%的跌幅還要嚴重。但是,可能只是股價受到了更廣泛的市場緊張情緒的影響。如果有很好的機會,可能值得關注基本面。不幸的是,去年的表現可能預示着尚未解決的挑戰,因爲它比過去五年0.8%的年化虧損還要糟糕。總的來說,長期股價疲軟可能是一個壞兆頭,儘管逆勢投資者可能希望研究該股以期出現轉機。長期跟蹤股價表現總是很有意思的。但是,要更好地了解江蘇索普化學,我們需要考慮許多其他因素。一個很好的例子:我們發現了你應該注意的江蘇索普化工的1個警告信號。

Of course Jiangsu SOPO Chemical may not be the best stock to buy. So you may wish to see this free collection of growth stocks.

當然,江蘇索波化工可能不是最好的買入股票。因此,您可能希望看到這批免費的成長股。

Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on Chinese exchanges.

請注意,本文引用的市場回報反映了目前在中國交易所交易的股票的市場加權平均回報。

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

對這篇文章有反饋嗎?對內容感到擔憂?直接聯繫我們。 或者,給編輯團隊 (at) simplywallst.com 發送電子郵件。
Simply Wall St的這篇文章本質上是籠統的。我們僅使用公正的方法根據歷史數據和分析師的預測提供評論,我們的文章無意作爲財務建議。它不構成買入或賣出任何股票的建議,也沒有考慮到您的目標或財務狀況。我們的目標是爲您提供由基本數據驅動的長期重點分析。請注意,我們的分析可能不考慮最新的價格敏感型公司公告或定性材料。簡而言之,華爾街沒有持有任何上述股票的頭寸。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論